Amino Acid Linker Structures for Protease-Stable Therapeutic Conjugates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapeutic conjugates face challenges with high toxicity and low efficacy due to the use of conventional linkers, which hinder their clinical application despite the potential of carrier molecules to enhance intracellular uptake.
Innovation Solution
The introduction of specific linkers with defined structures, such as Formula (I), which reduce toxicity by stabilizing the carrier-therapeutic conjugate orientation and protecting against protease cleavage, allowing for reduced toxicity and maintained efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional linkers are used to connect carrier molecules to therapeutic molecules, then the conjugate structure is formed, but toxicity increases and efficacy decreases
Solution Approach 1:
The patent applies parameter changes by modifying the linker structure from conventional designs to specific Formula (I) configurations. This involves changing the chemical parameters of the linker including the selection of T1 and T2 groups (amino or carbonyl), the value of n (1, 2, or 3), and the substitution patterns on the central carbon. These parameter modifications result in linkers that reduce toxicity while preserving therapeutic efficacy, directly resolving the contradiction between reliability and harmful factors.
Solution Approach 2:
The patent employs composite materials by creating a hybrid linker structure that combines multiple functional elements: amide or ester bonding capabilities (T1 and T2), flexible alkyl chains with variable substitution (R1 and R2 groups), and specific geometric configurations. This composite linker design integrates the benefits of different chemical moieties to achieve both low toxicity and high therapeutic efficacy, resolving the contradiction between these opposing requirements.
2Ease of operation
If the carrier molecule is optimized to enhance intracellular uptake, then cellular penetration improves, but toxicity increases
Solution Approach 1:
The patent applies the intermediary principle by introducing the specially designed linker as a mediating component between the carrier molecule and therapeutic molecule. The linker acts as a buffer or intermediary element that allows the carrier to maintain its cell-penetrating properties while preventing the toxic effects from transferring to the therapeutic payload. This intermediary structure resolves the contradiction by decoupling the uptake-enhancing function from the toxicity-generating function.
Data Source
AI summary
The present invention relates to linkers for connecting a carrier molecule to a therapeutic molecule to form a conjugate, in particular linkers formed of amino acids such as glutamic acid, succinic acid, and gamma-aminobutyric acid. The present invention further relates to a conjugate comprising a linker of the invention, and the use of the conjugate in the treatment of various diseases.